Gilead Sciences (GILD) closed at $153.57 in the latest trading session, marking a -1.88% move from the prior day. The stock fell short of the S&P 500, which registered a gain of 0.58% for the day. At the same time, the Dow added 0.69%, and the tech-heavy Nasdaq gained 1.05%.
Prior to today's trading, shares of the HIV and hepatitis C drugmaker had gained 2.52% lagged the Medical sector's gain of 3.5% and outpaced the S&P 500's gain of 0.97%.
The investment community will be closely monitoring the performance of Gilead Sciences in its forthcoming earnings report. The company is scheduled to release its earnings on October 29, 2026. The company is forecasted to report an EPS of $2.16, showcasing a 12.55% downward movement from the corresponding quarter of the prior year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $7.81 billion, up 0.59% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$0.47 per share and revenue of $30.76 billion, indicating changes of -105.77% and +4.47%, respectively, compared to the previous year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Gilead Sciences. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 1.14% higher. Gilead Sciences presently features a Zacks Rank of #2 (Buy).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 101, which puts it in the top 42% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Gilead Sciences, Inc. (GILD): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).